Sun, Mar 1, 2015, 6:39 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • ahhaha2 ahhaha2 Nov 3, 2012 12:40 AM Flag

    The CC, Q&A, Summer Street

    Ling Wang - Summer Street Research Partners

    With regard to the anecdotal Kyprolis combination yields. I was sort of wondering whether you can comment on whether the peers can monitor whether the drug is used as a single agent or in combination setting once they provide the preauthorization?

    You mentioned there are 7 oral presentations at ASH this year. Can you provide some color on that?

    What is the current projections on when Kyprolis will get the product-specific reimbursement code?


    Okay. In terms of Kyprolis, it's actually quite difficult for our payers or for the company, for that matter, to track whether they use as single-therapy use or in combination. So we don't really have any perspective on that one. And then I think, Barb, if you could talk a little bit about ASH.

    Barbara Klencke

    It's only a few days that ASH will, on their website, present the information. So I don't want to get ahead of the ASH announcement. Seven oral, so one is the company-sponsored oprozomib study, the Phase I efficacy, safety data, the Kyprolis, 6 oral, both a mix of investigator-sponsored data, as well as some of our own Phase II Kyprolis information.


    The permanent J Code should be available in January of 2014. These operate on a cycle prescribed by the federal government, and we expect J Code in that timing.

124.700.0000(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
PulteGroup, Inc.
NYSEFri, Feb 27, 2015 4:02 PM EST
AutoZone, Inc.
NYSEFri, Feb 27, 2015 4:05 PM EST